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Abstract
Meningococcal disease remains a public health burden in the UK and elsewhere.
Invasive Neisseria meningitidis, isolated in Scotland between 1972 and 1998, were
characterised retrospectively to examine the serogroup and clonal structure of the
circulating population. 2607 isolates causing invasive disease were available for
serogroup and MLST analysis whilst 2517 were available for multilocus sequence
typing (MLST) analysis only. Serogroup distribution changed from year to year but
serogroups B and C were dominant throughout. Serogroup B was dominant
throughout the 1970s and early 1980s until serogroup C became dominant during
the mid-1980s. The increase in serogroup C was not associated with one particular
sequence type (ST) but was associated with a number of STs, including ST-8, ST-
11, ST-206 and ST-334. This is in contrast to the increase in serogroup C disease
seen in the 1990s that was due to expansion of the ST-11 clonal complex. While
there was considerable diversity among the isolates (309 different STs among the
2607 isolates), a large proportion of isolates (59.9%) were associated with only 10
STs. These data highlight meningococcal diversity over time and the need for
ongoing surveillance during the introduction of new meningococcal vaccines.
Introduction
Neisseria meningitidis is an important cause of meningitis and bacteraemia
worldwide. The UK has experienced a changing meningococcal epidemiology in
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recent decades, which may be due to the cyclical pattern seen in meningococcal
serogroups as well as the implementation of meningococcal serogroup C (MenC)
vaccines [1, 2]. A MenC immunisation programme was implemented in the UK in
1999. The vaccine was highly effective in reducing the incidence of serogroup C
meningococcal disease and associated mortality, with no immediate adverse
effects on other serogroups [3–5]. However, the natural history of meningococcal
epidemiology is not well understood, particularly in relation to the long-term
effect of MenC immunisation on the meningococcal population. It is therefore
vital that the surveillance of meningococcal disease is continued. Long-term
retrospective data is required as most contemporary information relates to
immediately prior to or after the implementation of MenC vaccines. Although
data is available on meningococcal serogroups dating back to the 1970s, and
serogroup and serotype data is available from the 1990s, there is little molecular
data available from the 1970s onwards. Using the collection held at the Scottish
Haemophilus, Legionella, Meningococcus and Pneumococcus Reference
Laboratory (SHLMPRL) from 1972 onwards, we describe the serogroup and
clonal diversity of N. meningitidis in Scotland over several decades prior to the
introduction of MenC vaccines.
Materials and Methods
Ethical approval
This work was carried out as part of routine public health investigations by the
Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference
Laboratory. The SHLMPRL is the national reference service for the detection and
characterization of human Haemophilus, Legionella, Meningococcus and
Pneumococcus infections and the identification and typing of associated
environmental isolates. Patient consent was not required for this work. All data
was anonymised and only bacterial isolates were used; no human tissue or clinical
samples were used.
Bacterial isolates
All isolates of N. meningitidis from blood, cerebrospinal fluid (CSF) and other
normally sterile sites received by the SHLMPRL between 1972 and 1998 were
included in the study. Isolates originated from patients with reported invasive
meningococcal disease and were isolated at local diagnostic microbiology
laboratories in all NHS regions across Scotland. Only one isolate was used per
patient. Isolates were resuscitated from freeze-dried ampules in archive storage at
the SHLMPRL by culturing on Columbia horse blood agar (Oxoid, Basingstoke,
UK) and incubated overnight at 37 C˚ in 5% CO2.
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DNA extraction
DNA was isolated as previously described [6] and used directly for PCR. For those
freeze-dried meningococci that were not recoverable by culture, DNA was
amplified directly from the freeze-dried vial.
Isolate characterisation
Serogrouping was performed by latex agglutination when the meningococcal
isolates were first submitted to the reference laboratory [7]. Those found to be
non-groupable were characterised using siaD and mynA PCR as previously
described [8–10]. Molecular characterisation was performed by multilocus
sequence typing (MLST) based upon a semi-automated procedure [11]. The
analysis of nucleotide sequence data and assignment of alleles and assignment of
the allelic profile (otherwise known as the sequence type, ST) were performed as
previously described [4, 12]. Clonal comparisons were made using eBURST2 [13].
Results
Serogroup characterisation
2607 isolates of N. meningitidis were available for analysis. 1434 were from CSF,
913 from blood and 260 from other sites (including skin scraping, joint aspirate,
brain tissue, eye swab and rash fluid). There were 147 serogroup A isolates (5.6%),
1446 serogroup B isolates (55.5%), 812 serogroup C isolates (31.1%), 37
serogroup Y isolates (1.4%), 67 serogroup W isolates (2.6%), 10 serogroup X
isolates (0.4%), five serogroup Z isolates (0.2%) and six serogroup E isolates
(0.2%). Eighty-two isolates were initially non-groupable using latex agglutination
but PCR reduced that number to 19 (0.7%). A further 58 isolates (2.2%) could
not be characterised using either serogrouping or MLST by phenotypic or
molecular methods. Serogroup distribution changed from year to year. Serogroup
A meningococci were associated with 143 cases of invasive disease. The incidence
of serogroup A was higher during the 1970s before declining substantially. 134
isolates (94%) occurred between 1973 and 1982, followed by three cases in 1986,
two cases in 1987, one in 1989, one in 1992 and two in 1995. Serogroups B and C
were the dominant serogroups during the 1980s and 1990s (Fig. 1). Serogroups Y,
WI35, X, Z and E were also present in Scotland over this time period, representing
only 4.8% of the total.
Clonal analysis by MLST
There were 309 different STs with ten accounting for 1562 isolates (59.9%). These
were ST-11 (14.3%), ST-8 (14.2%), ST-41 (8.1%), ST-153 (5.4%), ST-1 (4.9%),
ST-32 (3.9%), ST-33 (2.9%), ST-269 (2.5%), ST-334 (1.9%) and ST-60 (1.9%).
The STs grouped into 31 distinct lineages, with 67 singleton types. There were 177
new STs which accounted for 253 (9.7%) isolates. The ST-8 complex was
predominant, accounting for 567 isolates (21.7%) (Table 1). This was represented
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by 21 different STs, the predominant being ST-8 (369, 65.1%), ST-153 (a gdh
locus variant of ST-8) (141, 24.9%), and ST-66 (a fumC locus variant of ST-8) (18,
3.2%).
MLST analysis by decade and serogroup
To determine the changes that might have occurred within the meningococcal
population during the study period, analysis was performed by splitting the data
Fig. 1. Distribution of invasive isolates associated with each serogroup, Scotland 1972-98.
doi:10.1371/journal.pone.0115741.g001
Table 1. Association of STs with predominant clonal complexes from Scotland 1972–98.
Clonal complexes
Number of
isolates
Number of
different STs STs present in double figures within clonal complex (%)
ST-8 567 21 ST-8 (65.1%) ST-153 (24.9%) ST-66 (3.2%)
ST-41/ST-44 422 51 ST-41 (49.7%) ST-206 (12.1%) ST-180 (6.4%) ST-43 (5.2%) ST-1362
(4.7%)
ST-11 393 12 ST-11 (95.1%) -
ST-32 239 21 ST-32 (42.7%) ST-33 (31.4%) ST-259 (8.0%) ST-343 (6.3%)
ST-1 133 5 ST-1 (96.2%)
ST-269 132 26 ST-269 (48.5%) ST-275 (24.2%)
ST-334 107 23 ST-334 (49.5%) ST-189 (14.0%) ST-415 (12.1%)
doi:10.1371/journal.pone.0115741.t001
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into the time periods 1972–1979, 1980–1989 and 1990–1998, to fit with the
suspected timing of the clonal expansion of MenC during the 1990s. Between 1972
and 1979 there were 616 isolates and these comprised 54 STs. There were 20
different clonal complexes and five singletons. Between 1980 and 1989 there were
845 isolates and these comprised 182 STs. There were 25 different clonal
complexes and 39 singletons. Between 1990 and 1998 there were 1146 isolates
comprising 160 STs. There were 27 different clonal complexes and 31 singletons.
The ST-8 complex was predominant during the 1980s and 1990s but declined
from 1993 in line with an increase in ST11. The ST41/44 complex was the next
most common during the 1980s and 1990s, two-thirds of which were serogroup B.
he ST-11 complex became dominant during the 1990s which was associated with
the specific emergence of serogroup C ST-11 meningococci and which coincided
with a reduction in the ST-8 strains which had been predominant during the
1980s and early parts of the 1990s.
Serogroup B isolates could be differentiated into 218 different STs, comprising
20 distinct lineages with 54 singleton types. Three lineages accounted for 888
isolates. The ST-41/44 complex was predominant with 333 isolates (23.0%) and
these were divided into 42 different STs.
Serogroup C isolates could be differentiated into 84 different STs, comprising
13 thirteen distinct lineages with 11 singleton types. Three lineages accounted for
664 isolates which represented 81.7% of all serogroup C isolates. The ST-11
complex accounted for the majority of isolates (328, 40.4%), these were divided
into eight STs, 314 were ST-11 (95.7%), three were ST-2510, three were ST-4644,
two were ST-3298 and ST-67, ST-2942, ST-3455 and ST-4677 were represented by
a single isolate. The ST-8 complex accounted for 243 isolates (29.9%) and they
were divided into nine different STs, 208 were ST-8 (85.6%), 15 were ST-66
(6.2%), and 13 were ST-153 (5.3%). Serogroup C was initially not associated with
a particular clone but the major STs included ST-8, ST-11, ST-206 and ST-334.
Nine STs were associated with serogroup A meningococci (ST-1, ST-5, ST-60,
ST-2002, ST-2174, ST-2152, ST-2517, ST-4570 and ST-4571). However, 88.7% of
isolates were ST-1. Serogroup Y isolates could be differentiated into 10 different
STs within three distinct lineages, with four singleton types. The ST-23 complex
was predominant accounting for 19 (51.4%) isolates of which six were isolated in
the 1970s, five in the 1980s and eight in the 1990s. Serogroup W isolates could be
differentiated into 11 different STs within four distinct lineages, with two
singleton types. The ST-11 complex was predominant with 42 isolates.
Discussion
Our long-term, nationwide study has provided a unique insight into the
molecular epidemiology of meningococci causing invasive disease within Scotland
in the period 1972–1998. Using serogroup and MLST data we have described the
clonal distribution of invasive meningococci prior to and during the emergence of
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MenC disease in the UK. Our data complements that described in other studies
performed during the implementation of MenC vaccines [2, 4, 14, 15].
Serogroup distribution changed from year to year in Scotland during the time
period 1972–1998, but serogroups B and C were dominant. Serogroup A was
present within the 1970s and early 1980s but has not re-established itself as a
major cause of meningococcal disease in the UK or elsewhere in Europe [16].
Serogroup B was the predominant serogroup throughout the 1970s and early
1980s until serogroup C became predominant during the mid-1980s. Although
serogroup Y meningococcal disease was a rare cause of invasive disease in
Scotland between 1972 and 1998 it is important that microbiologists are aware of
its potential for increasing in incidence after the introduction of MenC vaccines
[1].
Although there was diversity in the STs recovered between 1972 and 1998, ten
of these STs accounted for more than half of the isolates from the study. There is
extensive evidence for the persistence of particular genotypes among meningo-
coccal disease isolates [17, 18] and similar observations have been made with other
bacterial species [19]. In the present study, clonal complexes associated with seven
lineages accounted for 1993 isolates (76.4%). Thus, although there were infections
associated with novel STs, the majority of disease was associated with the same
predominant disease-associated complexes that have been found worldwide and
over a number of years [20, 21]. During the 1980s and 1990s, there was a noted
diversity at the complex, ST and singleton levels but there was less diversity in the
1970s. However, these results should be treated with caution as there was a 27%
increase in the number of isolates received at the reference laboratory between the
1970s and 1980s, and a similar increase between the 1980s and 1990s which may
affect the reported meningococcal diversity.
A number of studies have been performed with collections of meningococci.
For example, the EU-MenNet project analysed over 4000 European disease
isolates from 18 countries for three years from 2000 to 2002 [21–23]. Although its
findings were broadly similar to those of the present study, the isolates were from
the time period around MenC vaccine implementation. With the increasingly
widespread use of meningococcal polysaccharide and conjugate vaccines, one of
the continuing epidemiological concerns is the effect of immunisation on
serogroup replacement within the meningococcal population [24]. As the first
meningococcal serogroup B vaccine has now been licensed in Europe and
elsewhere [25], studies on meningococci from carriage and disease remain
important in order to monitor circulating meningococcal serogroups.
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